AIGH Capital Management LLC Purchases 4,517,227 Shares of IN8bio, Inc. (NASDAQ:INAB)

AIGH Capital Management LLC boosted its position in IN8bio, Inc. (NASDAQ:INAB) by 269.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,191,865 shares of the company’s stock after purchasing an additional 4,517,227 shares during the period. IN8bio makes up approximately 0.5% of AIGH Capital Management LLC’s investment portfolio, making the stock its 27th biggest holding. AIGH Capital Management LLC owned approximately 8.54% of IN8bio worth $1,593,000 at the end of the most recent quarter.

Separately, Sigma Planning Corp raised its holdings in shares of IN8bio by 22.3% in the fourth quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock worth $268,000 after buying an additional 190,100 shares during the period. Institutional investors own 92.05% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright dropped their price objective on IN8bio from $8.00 to $6.00 and set a “buy” rating for the company in a report on Friday, March 14th.

IN8bio Trading Down 5.8 %

INAB stock opened at $0.20 on Friday. IN8bio, Inc. has a 12 month low of $0.19 and a 12 month high of $1.74. The firm’s 50-day moving average is $0.26 and its 200 day moving average is $0.28. The company has a market capitalization of $15.93 million, a PE ratio of -0.26 and a beta of 0.03. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84.

IN8bio (NASDAQ:INAB) last issued its earnings results on Thursday, March 13th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. On average, research analysts anticipate that IN8bio, Inc. will post -0.56 EPS for the current year.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.